Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Spero Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 02:30PM GMT
Release Date Price: $1.73 (-6.49%)
Ram Selvaraju
H.C. Wainwright & Co., LLC - Analyst

Thank you so much for joining us for the next in our series of corporate presentations here at the H.C. Wainwright BioConnect Conference. My name is Ram Selvaraju. I'm the Managing Director and senior healthcare equity research analyst here at the firm.

It's my pleasure to introduce the next presenting company, which is Spero Therapeutics. Currently traded on the Nasdaq under the ticker symbol SPRO. We cover Spero Therapeutics with a buy rating. This is a company doing next-generation therapeutics development work in the anti-infective space.

Presenting for the company will be Sath Shukla, Chief Financial Officer. Sir, over to you.

Sath Shukla
Spero Therapeutics, Inc. - CFO

Thanks, Ram, for that introduction. And Thanks to HCW for having us here today.

So as Spero Therapeutics enters its first decade as a company, we are a leader in the infectious and rare disease space. The company has three late-stage medicines targeting indications with high unmet need and strong

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot